-transparent.png){kind=logo}
Ninety-one assessable patients with advanced oat cell and non-oat cell carcinoma of the lung were given AMSA on an intermittent every-3-week schedule. Starting doses ranged from 55 to 120 mg/m2, depending on the presence and severity of hepatic dysfunction. Three partial responses (two squamous cell carcinomas, one adenocarcinoma) of short duration were documented. The major toxic effect was leukopenia (44%). AMSA does not appear to have sufficient antitumor activity to warrant further investigation in advanced lung cancer.
Related Publications
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
March 1983,
Cancer treatment reports,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
January 1980,
Cancer treatment reports,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
February 1987,
American journal of clinical oncology,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
May 1982,
Cancer treatment reports,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
January 1982,
Cancer treatment reports,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
February 1982,
Cancer treatment reports,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
January 1981,
Cancer clinical trials,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
January 1986,
Oncology,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
January 1981,
Cancer chemotherapy and pharmacology,
M K Samson, and
R J Fraile, and
L H Baker, and
G Cummings, and
R W Talley
September 1985,
Cancer treatment reports,
